SCHEMBL19780935

SCHEMBL19780935

OB(O)c1ccc(-c2ccc(Cl)cc2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.54
KDM1A O60341 1/20 0.45
MAOB P27338 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMO O15229 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
METAP2 P50579 1/20 0.39
NOTUM Q6P988 1/20 0.39
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
FYN P06241 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
GRM2 Q14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954462 0.82 PIK3CD (0.42) ENPP2KDM4EALDH1A1NPC1RAB9A
SCHEMBL30518373 0.81 NPC1 (0.53) NPC1RAB9AORAI1ORAI2ORAI3
SCHEMBL14668828 0.81 CA2 (0.54) KDM1ANPC1RAB9ASMN1; SMN2METAP2
SCHEMBL2560337 0.81 NPC1 (0.53) NPC1RAB9AORAI1ORAI2ORAI3
SCHEMBL29950578 0.81 MGLL (0.54) ENPP2CA1CA2MGLL
SCHEMBL441703 0.81 MGLL (0.54) ENPP2CA1CA2MGLL
SCHEMBL38656446 0.80 ENPP2 (0.42) ENPP2KDM4ECA1CA2MGLL
SCHEMBL26314552 0.80 ENPP2 (0.42) ENPP2KDM4ECA1CA2MGLL
SCHEMBL31643901 0.77 ENPP2 (0.58) ENPP2KDM1AKDM4EALDH1A1CASP1
SCHEMBL27905589 0.77 F11 (0.56) KDM1ANPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 US disclosed
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
EP-3487865-B1 DINUCLEAR AND OLIGONUCLEAR METAL COMPLEXES CONTAINING TRIPODAL BIDENTATE PART LIGANDS AND THEIR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2022-11-23 EP disclosed
EP-3484868-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2020-11-25 EP disclosed
US-20190315787-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2019-10-17 US disclosed
US-20190157578-A1 DINUCLEAR AND OLIGONUCLEAR METAL COMPLEXES CONTAINING TRIPODAL BIDENTATE PART LIGANDS AND THEIR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2019-05-23 US disclosed
WO-2018019687-A1 DINUCLEAR AND OLIGONUCLEAR METAL COMPLEXES CONTAINING TRIPODAL BIDENTATE PART LIGANDS AND THEIR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2018-02-01 WO disclosed
WO-2018011186-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190157578-A1 DINUCLEAR AND OLIGONUCLEAR METAL COMPLEXES CONTAINING TRIPODAL BIDENTATE PART LIGANDS AND THEIR USE IN ELECTRONIC DEVICES SSBP1, POLRMT, BICRA ENPP2 1506/4885KDM1A 3645/4885MAOB 2506/4885
US-20190315787-A1 METAL COMPLEXES AP1M1, SOD1, AP3M1 ENPP2 2838/4885KDM1A 4139/4885MAOB 2625/4885
US-11713332-B2 Metal complexes AP1M1, SOD1, AP3M1 ENPP2 2838/4885KDM1A 4139/4885MAOB 2625/4885
US-20230322826-A1 METAL COMPLEXES AP1M1, SOD1, AP3M1 ENPP2 2838/4885KDM1A 4139/4885MAOB 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.